Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01218633 · ClinicalTrials.gov registry record · Phase 1
Dose-response Study of Exendin-9,39 on Glucose Metabolism
A Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01218633 is a Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 that has completed, run by Adrian Vella. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01218633, a Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.
Conditions Studied
Interventions
- DRUG saline infusion
- DRUG GLP-1-9,36 infusion
- DRUG Exendin-9,39 at low dose
- DRUG Exendin-9,39 at high dose
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01218633
The ClinicalTrials.gov registry entry for NCT01218633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrian Vella, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 appearing as the primary indexed condition, and to 4 interventions - of which saline infusion is the first listed.
NCT01218633 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01218633 about?
NCT01218633 is a clinical study titled "Dose-response Study of Exendin-9,39 on Glucose Metabolism". Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actio...
What is the current status of trial NCT01218633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-05. Estimated completion is 2012-12.
What conditions does trial NCT01218633 study?
This clinical trial studies the following conditions: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1.
What interventions are being tested in trial NCT01218633?
The interventions under investigation include: saline infusion (DRUG), GLP-1-9,36 infusion (DRUG), Exendin-9,39 at low dose (DRUG), Exendin-9,39 at high dose (DRUG).
Who is sponsoring clinical trial NCT01218633?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01218633 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.